INDICATIONS
Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.
For more information, please see the full Prescribing Information.
References: 1. Data on file, 2014-2018 Apoquel Brand Health, 2019, Zoetis Inc. 2. Data on file, Unique Patient Count from Launch, 2020, Zoetis Inc. 3. Data on file, Monthly VetStreet Report, December 2018, Zoetis Inc. 4. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. doi:10.1111/vde.12047. 5. Moriello KA. Canine allergic dermatitis: pathogenesis, clinical signs, and diagnosis. DVM 360. May 31, 2006. Accessed June 29, 2020. https://www.dvm360.com/view/canine-allergic-dermatitis-pathogenesis-clinical-signs-and-diagnosis. 6. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-e86. doi:10.1111/vde.12166. 7. Data on file, Study Report No. A161R-AU-12-096, Zoetis Inc. 8. Little PR, King VL, Davis KR, et al. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol. 2015;26(1):23-e8. doi:10.1111/vde.12186. 9. Data on file, Study Report No. 6962R-14-10-025, Zoetis Inc. 10. Data on file, Study Report No. 1962C-60-10-A16, Zoetis Inc. 11. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-e142. doi:10.1111/vde.12088. 12. Data on file, Study Report No. 1962C-60-09-930, Zoetis Inc. 13. Data on file, Pet Owner Case Study–Marley, Zoetis Inc. 14. Aleo MM, Galvan EA, Fleck TJ, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 15. Olivry T, Mueller RS, Prélaud P, et al. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res. 2015;11:225. doi:10.1186/s12917-015-0541-3. 16. Data on file, Press Release, 2014, Zoetis Inc. 17. Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101. 18. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13. doi:10.1016/j.mce.2010.04.005. 19. Guaguère E, Steffan J, Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol. 2004;15(2):61-74. doi:10.1111/j.1365-3164.2004.00376.x. 20. Data on file, Pet Owner Quantitative Market Research, 2013, Zoetis Inc. 21. Data on file, A Five-Year Post-Approval Safety Review for APOQUEL® in the US (May 2013 to August 2018), Zoetis Inc. 22. Volume 6C Summary of the Product Characteristics: SPC European Commission, Brussels. 1 Vol. 6C. July 10, 2006, 1-11. 23. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 24. Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 11, 2018, Zoetis Inc.25. Data on file, APOQUEL/CYTOPOINT Pet Tracker Wave 6, 2019, Zoetis Inc. 26. Data on file, APOQUEL Customer Survey, 2019, Zoetis Inc. 27. Data on file, APOQUEL Early Experience Program Pet Owner Aggregate Data, 2014, Zoetis Inc. 28. Data on file, Pet Owner Case Studies–Bijou, Nani, Gunner, Captain and Molly, Zoetis Inc.
LIKE US ON FACEBOOK
FOLLOW US ON INSTAGRAM